KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity (2016 - 2020)

Nektar Therapeutics has reported Debt to Equity over the past 10 years, most recently at $0.39 for Q1 2020.

  • Quarterly results put Debt to Equity at $0.39 for Q1 2020, up 159.22% from a year ago — trailing twelve months through Mar 2020 was $0.39 (up 159.22% YoY), and the annual figure for FY2019 was $0.18, up 25.15%.
  • Debt to Equity for Q1 2020 was $0.39 at Nektar Therapeutics, up from $0.18 in the prior quarter.
  • Over the last five years, Debt to Equity for NKTR hit a ceiling of $72.16 in Q2 2017 and a floor of -$880.47 in Q1 2016.
  • Median Debt to Equity over the past 5 years was $0.17 (2019), compared with a mean of -$46.97.
  • Biggest five-year swings in Debt to Equity: crashed 54551.96% in 2016 and later surged 1267.67% in 2017.
  • Nektar Therapeutics' Debt to Equity stood at $2.76 in 2016, then rose by 1.06% to $2.79 in 2017, then crashed by 94.85% to $0.14 in 2018, then grew by 25.15% to $0.18 in 2019, then skyrocketed by 118.17% to $0.39 in 2020.
  • The last three reported values for Debt to Equity were $0.39 (Q1 2020), $0.18 (Q4 2019), and $0.17 (Q3 2019) per Business Quant data.